

Information Regarding the ACIP Vote to Not Recommend LAIV Flu Vaccine for 2016-2017 Season

What Providers Need to Know for the Influenza Season

The Advisory Committee on Immunization Practices (ACIP) has voted that Live Attenuated Influenza Vaccine (LAIV), also known as the "nasal spray" flu vaccine, should not be used during the 2016-2017 flu season. ACIP continues to recommend annual flu vaccination for everyone 6 months and older.

Key Facts

- Based on CDC data, LAIV did not demonstrate enough evidence of effectiveness to warrant a recommendation.
- Preliminary estimates of vaccine effectiveness for LAIV among children 2 through 17 years during the 2015-2016 season was 3%, compared to Inactivated Influenza Vaccine (IIV) at 63%.
- The reason for decreased effectiveness with LAIV is currently unknown.
- The change in the ACIP recommendation is an example of using new available data to ensure public health actions are most beneficial.
- Final recommendations will be published in a CDC *Morbidity and Mortality Weekly Report* (MMWR) in late summer or early fall.

Provider Information

- Based on manufacturer projections, health officials expect that supply of IIV for the 2016-2017 season should be sufficient to meet any change in demand resulting from the ACIP recommendation.
- The Michigan Department of Health and Human Services (MDHHS) is working with CDC to ensure that the Vaccines for Children (VFC) supply is adequate.

MDHHS is actively seeking more information. As it becomes available, further updates will be sent. Questions? Contact Jalyng Ingalls, Influenza Epidemiologist, at IngallsJ@michigan.gov.